Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05233033 · ClinicalTrials.gov registry record · Phase 1
Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL
A Phase 1 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin Lymphoma, sponsored by Kymera Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 8
- Study locations
NCT05233033: Completed Phase 1 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin Lymphoma, sponsored by Kymera Therapeutics.
NCT05233033 is a Phase 1 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin Lymphoma that has completed, run by Kymera Therapeutics. The registered enrollment target is 7 participants, below the 219-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (97% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05233033, a Phase 1 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin Lymphoma, has completed, sponsored by Kymera Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 8
- Study locations
Study Summary
This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in patients with R/R NHL. The Phase 1a stage of the study will explore escalating doses of single-agent KT-413. The Phase 1b stage will be split into 2 expansion cohorts to further characterize the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in MYD88 mutant and MYD88 wild-type R/R DLBCL.
Primary Outcome
Phase 1a
Conditions Studied
Interventions
- DRUG KT-413
Study Locations (8)
Other
- University College London Hospitals - London
- University Hospital Southampton NHS Foundation Trust - Southampton
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Kentucky
- Norton Cancer Institute - Louisville
Michigan
- Henry Ford Health System - Detroit
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD Anderson Cancer Center - Houston
Virginia
- University of Virginia Comprehensive Cancer Center - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-06-13 |
| Est. Completion | 2023-07-28 |
| Phase | Phase 1 |
What the finished NCT05233033 record still lists
NCT05233033 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 219-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which KT-413 is the first listed.
NCT05233033 lists 8 locations in 7 states (Other, District of Columbia, Kentucky).
Frequently Asked Questions
What is clinical trial NCT05233033 about?
NCT05233033 is a clinical study titled "Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL". This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in patients with R/R NHL. The Phase 1a stage of the study will explore escalating doses of single-agent KT-413. The Phase 1b stage will be split into 2 expansion cohorts to fur...
What is the current status of trial NCT05233033?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2022-06-13. Estimated completion is 2023-07-28.
What conditions does trial NCT05233033 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Non-Hodgkin Lymphoma, DLBCL, MYD88 Gene Mutation.
What interventions are being tested in trial NCT05233033?
The interventions under investigation include: KT-413 (DRUG).
Who is sponsoring clinical trial NCT05233033?
This trial is sponsored by Kymera Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05233033 being conducted?
This trial has 8 study locations across District of Columbia, Kentucky, Michigan, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05233033's enrollment target sits among peer trials
7 112th of 114 higher than 3 of 114 other Diffuse Large B Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
RECRUITING · Phase 1
-
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI